STOCK TITAN
  1. Home
  2. News
  3. BGNE

BeiGene Ltd - BGNE STOCK NEWS

Welcome to our dedicated news page for BeiGene (Ticker: BGNE), a resource for investors and traders seeking the latest updates and insights on BeiGene.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BeiGene's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BeiGene's position in the market.

News
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
Rhea-AI Summary
BeiGene, a global oncology innovator, is set to present new data at the 2024 ASCO Annual Meeting showcasing the efficacy and safety of BRUKINSA and TEVIMBRA across various B-cell malignancies and solid tumors. The company will highlight BRUKINSA's differentiated clinical profile and present data comparing its efficacy with other treatments in chronic lymphocytic leukemia. TEVIMBRA will be featured in multiple presentations, demonstrating its potential across different tumor types. The company's solid tumor development program will be a focal point at the meeting, with new data from the RATIONALE-306 study on TEVIMBRA's efficacy in esophageal squamous cell carcinoma. BeiGene's commitment to addressing unmet patient needs through innovative treatments is evident in the research outcomes they will share at ASCO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
Rhea-AI Summary
BeiGene receives European Commission approval for tislelizumab as a treatment for non-small cell lung cancer, marking the second approval in the region. The comprehensive development program included three Phase 3 clinical trials demonstrating the benefits of tislelizumab for both treatment-naïve and relapsed NSCLC patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.15%
Tags
none
-
News
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
Rhea-AI Summary
BeiGene's TEVIMBRA receives FDA approval for treating adult patients with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy, showing significant survival benefits in Phase 3 RATIONALE 302 trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.65%
Tags
fda approval
News
Pi Health Raises Over $30M in Series A to Revolutionize Cancer Care and Clinical Trials
Rhea-AI Summary
Pi Health, a subsidiary of BeiGene, Ltd. (NASDAQ: BGNE), secures over $30M in Series A funding to revolutionize global access to clinical trials and innovative medicines. The funding round, led by AlleyCorp and Obvious Ventures, aims to address the inefficiencies in the clinical trial process by leveraging cutting-edge technology. Pi Health's FICS software streamlines data collection and accelerates drug development, potentially saving lives and reducing costs. The company's mission is to democratize cancer care and research by increasing patient enrollment and enhancing global access to life-saving treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.29%
Tags
clinical trial
-
News
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
Rhea-AI Summary
Armenia and Nepal are the first countries to receive BRUKINSA, a treatment for chronic lymphocytic leukemia, as part of a collaboration between Max Foundation, BeiGene, and BeiGene Foundation. The initiative aims to provide access to the medicine in 29 low- and middle-income countries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.77%
Tags
none
-
News
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
Rhea-AI Summary
BeiGene's BRUKINSA receives accelerated approval from the FDA for the treatment of relapsed or refractory follicular lymphoma in combination with obinutuzumab, marking its fifth indication in B-cell malignancies. The approval is based on positive results from the ROSEWOOD trial, showcasing higher overall response rates. BRUKINSA is the first and only BTK inhibitor to show efficacy in this type of malignancy, with a broad label covering five oncology indications globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.3%
Tags
none
News
BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
Rhea-AI Summary
BeiGene presents promising data on tislelizumab-containing immuno-oncology combinations and BGB-16673 at AACR 2024, showcasing advancements in cancer treatment and novel mechanisms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
conferences clinical trial
-
News
BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
Rhea-AI Summary
BeiGene, Ltd. announces a new analysis comparing BRUKINSA and acalabrutinib in CLL, showing potential efficacy advantages for BRUKINSA in progression-free survival, complete response, and overall survival. The MAIC data will be presented at a congress in Miami. BRUKINSA is the only BTK inhibitor to demonstrate superiority over ibrutinib in R/R CLL. Acalabrutinib has shown improvement in progression-free survival in different trials. The analysis suggests BRUKINSA's superiority over acalabrutinib in progression-free survival and complete response.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.19%
Tags
none
-
News
BeiGene to Present at Upcoming Investor Conferences
Rhea-AI Summary
BeiGene, Ltd. (BGNE) will participate in fireside chats at two investor conferences, TD Cowen 44th Annual Health Care Conference and Leerink Partners Global Biopharma Conference. Live webcasts can be accessed on BeiGene's website, with archived replays available for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
conferences
News
BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
Rhea-AI Summary
BeiGene, Ltd. announces FDA acceptance of BLA for TEVIMBRA in combination with chemotherapy for advanced gastric/GEJ cancer treatment. Results from RATIONALE-305 trial show significant overall survival improvement. FDA action date set for December 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.12%
Tags
none
Stock BGNE logo
BeiGene Ltd

Nasdaq:BGNE

BGNE Rankings

#608 Ranked by Market Cap
#1946 Ranked by Stock Gains
N/A Ranked by Dividends

BGNE Stock Data

14.97B
762.01M
0.03%
48.09%
1.65%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
China (Mainland)
Changping District

About BGNE

BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.